uniQure

#Clinical trial #Huntington's disease #Regulatory #uniQure

From the Editor: Terms and Conditions

The recent report that pharmaceutical company uniQure’s data from its Phase I/II studies provide insufficient evidence for the approval of its investigational gene therapy drug for Huntington’s disease (HD) are a major blow for patients.  Huntington’s disease is a rare genetic disorder that can affect around 5-10 people per 100,000, and which is… Read More

#Exclusive Content #Opinion

#Ascendis Pharma #BioIndustry Association #Cancer therapy #CHMP #Clinical trial #Diversity #European Medicines Agency #FDA #Gene therapy #Oncology #Paediatrics #Rare disease #uniQure #University of Queensland #Women in STEM

DDW Highlights: 10 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, figures showed the number of women in biotech leadership has stalled. Elsewhere, could… Read More

#Podcasts

#Advanced Therapies #FDA #Gene therapy #Huntington's disease #uniQure

Investors file lawsuit against uniQure following FDA ruling

The US Food and Drug Administration (FDA) has ruled that data from Phase I/II studies are insufficient evidence to approve the marketing authorisation for uniQure’s AMT-130, an investigational gene therapy for Huntington’s disease (HD).   In response, investors have issued a class action securities lawsuit to recover losses.  The FDA said… Read More

#Business & Investment #News #Trending News

Gene therapy
#Gene editing #Gene therapy #Genetic diseases #Huntington's disease #uniQure

Trial shows slowing of Huntington’s progression for the first time

A global clinical trial for a new Huntington’s disease gene therapy has posted positive results, including 75% less progression of the disease.  AMT-130 is the first gene therapy to be tested in people with Huntington’s. This is also the first time a drug trial has reported continuing,… Read More

#News #Trending News